tadalafil has been researched along with Cruveilhier-Baumgarten Syndrome in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Deibert, P; Kreisel, W; Lazaro, A; Rössle, M; Schaffner, D; Stankovic, Z | 1 |
| Miyasaka, A; Morino, Y; Suzuki, A; Takikawa, Y; Ueda, H; Yoshida, Y | 1 |
| Kalambokis, GN; Kosta, P; Pappas, K; Tsianos, EV | 1 |
| Bremer, H; Deibert, P; Kreisel, W; Kurz-Schmieg, AK; Roessle, M | 1 |
4 other study(ies) available for tadalafil and Cruveilhier-Baumgarten Syndrome
| Article | Year |
|---|---|
Beneficial long term effect of a phosphodiesterase-5-inhibitor in cirrhotic portal hypertension: A case report with 8 years follow-up.
Topics: Administration, Oral; Cholangitis, Sclerosing; Computed Tomography Angiography; Endoscopy, Digestive System; Esophageal and Gastric Varices; Female; Follow-Up Studies; Gastrointestinal Hemorrhage; Hemodynamics; Hepatitis, Autoimmune; Humans; Hypertension, Portal; Liver Cirrhosis; Middle Aged; Phosphodiesterase 5 Inhibitors; Syndrome; Tadalafil; Time Factors; Treatment Outcome; Vardenafil Dihydrochloride | 2018 |
A case of suspected portal-pulmonary hypertension due to hepatitis C virus infection.
Topics: Adult; Antiviral Agents; Cardiac Catheterization; Echocardiography; Echocardiography, Doppler; Endothelin Receptor Antagonists; Female; Hepatitis C, Chronic; Humans; Hypertension, Portal; Liver Cirrhosis; Phosphodiesterase 5 Inhibitors; Pulmonary Arterial Hypertension; Pyrimidines; Sulfonamides; Sustained Virologic Response; Tadalafil; Treatment Outcome; Tricuspid Valve Insufficiency; Ventricular Dysfunction, Right | 2020 |
Haemodynamic and renal effects of tadalafil in patients with cirrhosis.
Topics: Carbolines; Hemodynamics; Humans; Hypertension, Portal; Kidney; Liver Cirrhosis; Natriuresis; Phosphodiesterase Inhibitors; Tadalafil; Vasodilator Agents | 2010 |
PDE-5 inhibitors lower portal and pulmonary pressure in portopulmonary hypertension.
Topics: 3',5'-Cyclic-GMP Phosphodiesterases; Carbolines; Cyclic Nucleotide Phosphodiesterases, Type 5; Humans; Hypertension, Portal; Hypertension, Pulmonary; Male; Middle Aged; Phosphodiesterase Inhibitors; Tadalafil | 2007 |